Part 2 - Preparing for the FDA Panel on Aducanumab: Discussing the Briefing Documents with a Neurologist before the Ad-comTicker(s): BIIB
Name: Dr Russell Swerdlow - MD
Institution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease and very familiar with the Aducanumab public literature.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.